Products for Research Use Only
RegisterLogin

Osilodrostat (Standard)

CAT: 0804-HY-16276R-04Size: 25 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-16276R-04Size:25 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Osilodrostat (Standard) is the analytical standard of Osilodrostat. This product is intended for research and analytical applications. Osilodrostat (LCI699) is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat inhibits aldosterone and corticosterone synthesis. Osilodrostat has blood pressure lowering ability. Osilodrostat can be used for research of Cushing syndrome (CS) [1][2][3].
CAS Number
928134-65-0
UNSPSC
12352100
Target
Mineralocorticoid Receptor; Reference Standards
Related Pathways
Metabolic Enzyme/Protease; Others; Vitamin D Related/Nuclear Receptor
Field of Research
Cancer; Inflammation/Immunology; Cardiovascular Disease
Smiles
N#CC1=CC=C([C@H]2CCC3=CN=CN32)C(F)=C1
Molecular Formula
C13H10FN3
Molecular Weight
227.24
References & Citations
[1]Ménard J, et, al. Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects. J Transl Med. 2014 Dec 10;12:340.|[2]Creemers SG, et, al. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study. J Clin Endocrinol Metab. 2019 Aug 1;104 (8) :3437-3449.|[3]Li L, et, al. Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats. Toxicol Appl Pharmacol. 2015 Aug 1;286 (3) :224-33.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards

Chemical Information

Osilodrostat

Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013. Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. Cushing's disease), and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication.

CAS Number928134-65-0
PubChem CID44139752
IUPAC Name4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile
Molecular FormulaC13H10FN3
Molecular Weight227.24
XLogP1.9
Topological Polar Surface Area41.6
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count3
Rotatable Bond Count1
Heavy Atom Count17
Formal Charge0
Complexity337
SMILES
C1CC2=CN=CN2[C@H]1C3=C(C=C(C=C3)C#N)F
InChI
InChI=1S/C13H10FN3/c14-12-5-9(6-15)1-3-11(12)13-4-2-10-7-16-8-17(10)13/h1,3,5,7-8,13H,2,4H2/t13-/m1/s1
InChIKey
USUZGMWDZDXMDG-CYBMUJFWSA-N
Chemical Structure
2D Structure
2D structure of Osilodrostat
CAS: 928134-65-0
CID: 44139752
Formula: C13H10FN3
MW: 227.24
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight227.24
XLogP31.9
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count3
Rotatable Bond Count1
Exact Mass227.08587549
Monoisotopic Mass227.08587549
Topological Polar Surface Area41.6 Ų
Heavy Atom Count17
Formal Charge0
Complexity337
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Related Products

CatalogName
HY-16276-01Osilodrostat
HY-16276A-01Osilodrostat (phosphate)
HY-P2274RArgifin (Standard)
HY-N9362REmodinanthrone (Standard)
HY-N7948RIsomaltotetraose (Standard)
HY-N7640RDeoxylimonin (Standard)
HY-N7617RToralactone (Standard)
HY-N7541RAntrodin A (Standard)
HY-N6739RBeauvericin (Standard)
HY-N6687RCalcimycin (Standard)

Alternative Products

CatalogName
B3108-5Osilodrostat
T28272-01Osilodrostat phosphate
MBS3840152-01LCI-699 (Osilodrostat)
S7456-2mgOsilodrostat (LCI699)
CS-O-61405Osilodrostat d4
A14013-50LCI-699 (Osilodrostat) 50mg
A14013-1LCI-699 (Osilodrostat) 1mg
GTR19153855-01Osilodrostat (LCI699) phosphate
205909Osilodrostat free base
A14013-100LCI-699 (Osilodrostat) 100mg

Popular Products